BioXcel Therapeutics, Inc. (BTAI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
the bull case· 3
+80.00%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '2642
managers reporting a position in thirteen f filings
13fJun 30 '262 of 16
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26the bear case· 1
6
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 13 '26 report. Not a forecast, not advice.
tall tick = annual report · 1 on record
BioXcel Therapeutics, Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
BioXcel Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 0.10 at 4:00 am ET, low 0.04 at 6:15 pm ET.
BTAI (BioXcel Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
43 managers report a position worth $8.6M between them, and 6 of them hold 80% of it.